You are here: Industry Insights > Indivior

News List

Indivior and Aelis enter $130m deal for cannabis addiction therapy pharmaceutical-technology
June 10, 2021
Indivior has entered a strategic partnership and an exclusive option and licence agreement with France-based Aelis Farma for worldwide rights to the latter’s lead compound, AEF0117.
Indivior lays out restructuring plans to cut down expenses pharmaceutical-technology
September 27, 2020
UK-based pharmaceutical firm Indivior has stated that it is taking organisational and cost actions to adjust its abilities and resources to meet its strategic priorities.
Indivior to pay $600m to settle opioid drug marketing claims pharmaceutical-technology
July 28, 2020
Indivior has reached an agreement to pay $600m to settle US claims that the company had run an illegal scheme to increase prescriptions of its opioid addiction treatment, Suboxone.
Indivior indicted in US over marketing practices for opioid addiction treatment Suboxone Film; shares crash firstwordpharma
April 11, 2019
Indivior indicted in US over marketing practices for opioid addiction treatment Suboxone Film; shares crash.
Indivior Announces Launch of SUBOXONE Sublingual Film Generic americanpharmaceuticalreview
February 22, 2019
Indivior announced its U.S. affiliate, Indivior Inc., has launched an authorized generic version of SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) in the U.S. The authorized generic is being marketed and .....
US top court denies Indivior’s request on suboxone, Dr Reddy’s gains Hyderabad expressbpd
February 21, 2019
Indivior is in legal battle against the launch of copycat version of its opioid addiction treatment by competitors including Dr Reddy’s Laboratories in the US market
Indivior launches generic version of Suboxone sublingual film pharmaceutical-technology
February 21, 2019
UK-based pharmaceutical company Indivior has launched a generic version of its Suboxone (buprenorphine and naloxone) sublingual film in the US for the treatment of opioid dependence....
Indivior's new antipsychotic wins FDA nod, but Suboxone patent fight could delay its launch fiercepharma
August 01, 2018
Just as Indivior stalled Dr. Reddy’s rollout of a generic to its top-selling drug, Suboxone Film, the launch of a new drug of Indivior’s own might become collateral damage of the patent fight and the slow ramp-up of fellow newcomer Sublocade.
Indivior shares soar as US judge rules against Dr Reddy pharmafile
July 17, 2018
Shares in the London listed addiction specialist Indivior surged in price today, as the Indian pharmaceutical company Dr Reddy’s Laboratories was blocked from selling generic versions of Indivior’s bestselling opioid addiction treatment, Suboxone Film, in
Addex, Indivior Forge $335M Addiction Disorder Tie-Up biospace
January 04, 2018
Indivior today announced that Indivior UK Limited has entered into a strategic collaboration with Addex Pharma S.A., a wholly-owned subsidiary of Addex Therapeutics (SIX: ADXN) ("Addex"), in the field of GABAB positive allosteric modulators

Previous page 1 2 Next page